Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SEEVOTF 58 EV-to-EBITDA is -3.21 as of Aug. 03, 2026. GuruFocus rates EVOTF with a GF Score™ of 58/100 and a GF Value™ of $13.95. The stock has 5 warning signs investors should review. Among 746 Drug Manufacturers companies, Evotec SE ranks worse than 134048.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Evotec SE's enterprise value is $610.3 Mil.
Evotec SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-190.3 Mil. Therefore, Evotec SE's EV-to-EBITDA for today is -3.21.
The historical rank and industry rank for Evotec SE's EV-to-EBITDA or its related term are showing as below:
EVOTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.04 Med: 33.53 Max: 168.44
Current: -3.22
During the past 13 years, the highest EV-to-EBITDA of Evotec SE was 168.44. The lowest was -59.04. And the median was 33.53.
EVOTF's EV-to-EBITDA is ranked worse than 100% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs EVOTF: -3.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Evotec SE's share price for today is $6.69.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Evotec SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evotec SE's EV-to-EBITDA falls into.
Evotec SE's current Enterprise Value is $610.3 Mil.
Evotec SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-190.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVOTF) has a EV-to-EBITDA of -3.21 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Evotec SE. According to the industry distribution chart, Evotec SE ranks #999999 out of 746 companies in the Drug Manufacturers industry.
Is Evotec SE's EV-to-EBITDA too high?
Evotec SE's current EV-to-EBITDA is -3.21. Based on the distribution chart, Evotec SE ranks #999999 out of 746 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #999999 out of 746 companies for EV-to-EBITDA. This places Evotec SE in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Evotec SE. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current EV-to-EBITDA is -3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (EVOTF) has a current EV-to-EBITDA of -3.21. The stock's GF Value™ is $13.95, compared to a current price of $6.69 — trading 52% below its estimated fair value. The current EV-to-EBITDA is -3.21. Evotec SE's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Evotec SE (EVOTF), the current EV-to-EBITDA is -3.21 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVOTF) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $6.69 is trading 52% below its estimated GF Value™ of $13.95.
Key valuation signals for EVOTF:
EV-to-EBITDA: -3.21
GF Value™: $13.95 vs. price of $6.69 (52% below fair value)
No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
58GF Score
Get the complete analysis for EVOTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVOTF has been successfully added to your 
